bevacizumab

Type: Keyphrase
Name: bevacizumab
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Go-ahead for PledPharma to also include Avastin patients in Part 2 of the PLIANT study

Stockholm, 2014-04-23 08:30 CEST (GLOBE NEWSWIRE) --PledPharma has received approval from the DSMB (Drug Safety Monitoring Board,an independent panel of experts) to also include patients being treated with acombination of FOLFOX and Avastin (bevacizumab) ... [Published EuroInvestor - 8 hours ago]
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit ...

Colorectal cancer (CRC) is a disease of the elderly. However, geriatric patients are often excluded from clinical trials.The combination of capecitabine, oxaliplatin and bevacizumab (XELOX/BEV) has not been assessed in an elderly population.Methods: We ... [Published 7thSpace - 21 hours ago]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Researchers at Gazi University Report New Data on Diabetes

(NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Current study results on Diabetes have been published. According to news reporting from Ankara, Turkey, by NewsRx journalists, research stated, "To assess the effect of intravitreal ... [Published NewsRX - Apr 19 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Maintenance Therapy for Colorectal Cancer

Maintenance therapy has become quite a hot topic for those of us working in the field of solid tumor malignancies. Our original concept of chemotherapy for solid tumors was to give a certain number of cycles and then stop treatment, or to continue treatment ... [Published Cancernetwork.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Addition of bevacizumab to chemotherapy improved QOL in ovarian cancer

The addition of bevacizumab to chemotherapy improved abdominal or gastrointestinal symptoms among patients with platinum-resistant ovarian cancer, according to analyses of phase 3 study results.The AURELIA trial included 361 patients with platinum-resistant ... [Published Orthopedics Today - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Sales of cancer drugs soar once again at Roche

Roche has posted a strong set of financials for the first quarter, again bolstered by its cancer drugs.
Sales reached 11.50 billion francs, a dip of 1% due to the impact of currency, while pharmaceutical revenues also fell 1% to 9.04 billion francs; Roche ... [Published Pharma Times - Apr 16 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Bevacizumab in Treatment of High-Risk Ovarian Cancer--A Cost-Effectiveness Analysis

Objective. The objective of this study was to evaluate a cost-effectiveness strategy of bevacizumab in a subset of high-risk advanced ovarian cancer patients with survival benefit.Methods. A subset analysis of the International Collaboration on Ovarian ... [Published The Oncologist - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

VIDEO: Surgeon discusses the controversy over ranibizumab vs. bevacizumab

At the  World Ophthalmology Congress in Tokyo, Matteo Piovella, MD, discusses the need for  evidence-based medicine in discerning between  Avastin vs. Lucentis .CommentsHealio is intended for health care provider use and all comments will be posted at ... [Published Orthopedics Today - Apr 10 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Avastin, Once Considered Promising for Glioblastoma, Disappoints in Large Trial

Two new reports found that the monoclonal antibody that targets vascular endothelial growth factor A showed improvement in the duration of progression-free survival — by three to four months — for glioblastoma, but did not impact overall survival.Results ... [Published Neurology Today - Apr 04 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

[News] Bevacizumab for advanced cervical cancer

Addition of bevacizumab to chemotherapy increases overall survival in advanced cervical cancer that is not curable with existing standard therapy, according to a new study . Although in developed countries the incidence of cervical cancer has been decreasing, ... [Published Lancet Oncology - Mar 31 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Research report on Chinas bevacizumab market

chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs. As ... ... [Published Big News Network - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

UK Cancer Drugs Fund Adds Roche, Celgene Corporation And Exelixis, Inc. Drugs

Three new drugs have been added to the Cancer Drugs Fund (CDF) in a move NHS England says could benefit 900 patients per year. The Fund will add new NHS coverage in England for Roche's Avastin (bevacizumab), Celgene's Abraxane (albumin bound paclitaxel) ... [Published BioSpace - Mar 24 2014]

Quotes

The news correspondents obtained a quote from the research from Gazi University, "Intravitreal... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."
...dosing schedule is designed to achieve a higher concentration (Cmax) and exposure (AUC) compared to the NCI dosing regimen," added Mr Bacha. "We are hopeful that our strategy to modernize the dosing regimen will build upon the clinical promise of previous NCI-sponsored clinical trials and eventually provide physicians with an important new treatment for patients suffering from glioblastoma."
...Roche denied that the two companies had colluded: "Roche confirms there is no agreement between Roche and Novartis that restricts competition,” stated Reuters."
According to the news editors, the research concluded: "Our preliminary findings showed the potential of USPIO as an imaging agent for the SPECT/MRI of HepG2 HCC."

More Content

All (206) | News (175) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Kala Pharma Grabs $22.5M More For Eye Drugs [Published Xconomy - 3 hours ago]
Go-ahead for PledPharma to also include Avastin... [Published GlobeNewswire: Advertising News - 8 hours ago]
Go-ahead for PledPharma to also include Avastin... [Published EuroInvestor - 8 hours ago]
Multiple lines of targeted therapy extend life ... [Published News-Medical.Net - 17 hours ago]
Capecitabine in combination with oxaliplatin an... [Published 7thSpace - 21 hours ago]
Striae Distensae: Prophylaxis and Treatment [Published General Medicine eJournal - 21 hours ago]
Researchers at Gazi University Report New Data ... [Published NewsRX - Apr 19 2014]
ASCRS issues clinical alert on eye-whitening pr... [Published Eye World - Apr 17 2014]
Maintenance Therapy for Colorectal Cancer [Published Cancernetwork.com - Apr 17 2014]
Boehringer lines up biosimilars of major drugs [Published PMLive - Apr 17 2014]
Epirus to acquire Zalicus, creating a publicly-... [Published Pharma Letter - Apr 17 2014]
Addition of bevacizumab to chemotherapy improve... [Published Orthopedics Today - Apr 16 2014]
DelMar announces encouraging results from Phase... [Published Individual.com - Apr 16 2014]
Sales of cancer drugs soar once again at Roche [Published Pharma Times - Apr 16 2014]
Safety Issues With Bisphosphonate Therapy for O... [Published General Medicine eJournal - Apr 16 2014]
Roche starts 2014 with sales dip due to strong ... [Published Pharma Letter - Apr 15 2014]
Roche may face EU levies following drug safety ... [Published Pharmafocus - Apr 15 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
A Conversation With David I. Quinn, MBBS, PhD, ... [Published The ASCO Post - Apr 15 2014]
Revamp the FDA Drug-Approval Process [Published Diabetes Care - Apr 14 2014]
France moving ahead with biosmilar substitution [Published Pharma Times - Apr 13 2014]
Star obtains list of red-flagged drugs [Published Toronto Star Online - Apr 12 2014]
Bevacizumab in Treatment of High-Risk Ovarian C... [Published The Oncologist - Apr 11 2014]
Asia Pacific Solid Tumors Market 2013-2019 [Published Individual.com - Apr 11 2014]
VIDEO: Surgeon discusses the controversy over r... [Published Orthopedics Today - Apr 10 2014]
French competition authority investigating Roch... [Published Pharma Letter - Apr 10 2014]
Cerulean Limps into Nasdaq Debut With $7 Per Sh... [Published Xconomy - Apr 10 2014]
:: Alimera awaits Iluvien decision [Published Retinal Physician - Apr 10 2014]
New Hepatocellular Carcinoma Study Findings Hav... [Published HispanicBusiness.com - Apr 10 2014]
French competition authorities raid Roche, Nova... [Published FirstWord Pharma - Apr 10 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 08 2014]
Investigation Report on China Bevacizumab Marke... [Published PR Newswire: General Business - Mar 25 2014]
DUBLIN, March 25, 2014 /PRNewswire/ -- Research  and  Markets (http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to... ...
Research and Markets: Investigation Report on C... [Published Business Wire Health News - Mar 10 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rj2tm7/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering. Bevacizumab is an ...
Adding Bevacizumab To Initial Glioblastoma Trea... [Published Scientific Blogging - Medicine - Mar 04 2014]
Glioblastoma is the most common primary malignant adult brain tumor and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months. Few patients live beyond five years.Glioblastom ...
Adding Bevacizumab To Initital Glioblastoma Tre... [Published Scientific Blogging - Mar 04 2014]
Glioblastoma (GBM) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months with few patients living beyond five years. ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Go-ahead for PledPharma to also include Avastin... [Published GlobeNewswire: Advertising News - 8 hours ago]
Cortice Announces Enrollment of a Phase 2 Trial... [Published GlobeNewswire: Advertising News - Mar 20 2014]
MDxHealth's PredictMDx for Glioblastoma Identif... [Published GlobeNewswire: Advertising News - Mar 04 2014]
Cortice Announces Enrollment of a Phase 2 Trial... [Published GlobeNewswire: Advertising News - Jan 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.